LGALS3 and ductal breast carcinoma in situ: The ITRAQ data was confirmed by immunoblotting (Figure 3B) and is consistent with another study that described detectable expression of Galectin 3 in normal ducts and down-regulation in ductal carcinoma in situ[37].